Business · 02/07/2021
FDA Announces Final Guidance for Evaluating Cancer Drugs in Patients with Central Nervous System Metastases
The FDA has released a final guidance document outlining recommendations for clinical trials of cancer drugs targeting patients with central nervous system metastases from solid tumors, in an effort to support product labeling claims of antitumor activity.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →